But in a well-designed fat loss stack particularly alongside a GLP-1 agonist it earns its place
I., Fichman, Y
The interplay among gut microbiota, hypertension and kidney diseases: the role of short-chain fatty acids
(Waldner 2006) A double-blind RCT (n=30) in patients receiving high-dose interleukin-2 therapy reported a reduction in serious cardiac events (e.g., arrhythmias and acute heart failure) with L-carnitine use compared to no therapy, but the small sample size and heterogeneity of the cancer types limit generalizability
Lee WC, Reuben A, Hu X, McGranahan N, Chen R, Jalali A, Negrao MV, Hubert SM, Tang C, Wu CC, Lucas AS, Roh W, Suda K, Kim J, Tan AC, Peng DH, Lu W, Tang X, Chow CW, Fujimoto J, Behrens C, Kalhor N, Fukumura K, Coyle M, Thornton R, Gumbs C, Li J, Wu CJ, Little L, Roarty E, Song X, Lee JJ, Sulman EP, Rao G, Swisher S , Diao L, Wang J, Heymach JV, Huse JT, Scheet P, Wistuba II, Gibbons DL, Futreal PA, Zhang J, Gomez D, Zhang J
Zhang P, Zhou C, Ren X, Jing Q, Gao Y, Yang C, et al